多囊卵巢综合征患者血清IL-22和游离脂肪酸与糖脂标记物相关性的研究

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (852 KB) HTML (0 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探索肠道免疫因子IL-22、游离脂肪酸和糖脂标记物在中国女性多囊卵巢综合征(PCOS)中的诊断价值及其相关性,为PCOS的诊断和管理提供合理的参考。方法 2015年9月—2016年12月在北医三院生殖中心初诊符合鹿特丹PCOS诊断标准的PCOS女性患者24例,纳入PCOS组。同期在本院体检中心体检正常的健康女性24例,纳入对照组。比较两组的IL-22水平、游离脂肪酸水平,分析IL-22、游离脂肪酸与糖脂标记物的相关性。结果 PCOS患者血清中IL-22水平较正常对照组降低(P<0.01)。PCOS组患者的游离脂肪酸较比照组明显升高,主要表现为十四烷酸(FFA 14:0)、示十八烷酸/硬脂酸(FFA 18:0)、十八碳一烯酸(FFA 18:1)、亚油酸(FFA 18:2)及二十二碳六烯酸/DHA(FFA 22:6)比对照组升高(P<0.05)。IL-22与空腹血糖、空腹胰岛素、HOMA-IR及TG均有相关性,且呈负相关关系(P<0.05)。结论 PCOS患者血清免疫因子IL-22明显降低,血清游离脂肪酸明显升高,且患者的糖脂标记物与IL-22有一定的相关性,可能与PCOS患者的肠道免疫失调,导致IL-22下降有关。IL-22可以作为早期预测PCOS患者代谢异常严重程度的指标之一。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	齐新宇
	庞艳莉
	乔杰

关键词 ：多囊卵巢综合征, IL-22, 游离脂肪酸, 代谢异常

Abstract：Objective To investigate the diagnostic value and relationship of intestinal immune factor IL-22, free fatty acids and glycolipid markers levels in Chinese women with polycystic ovary syndrome (PCOS), and to provide a reasonable reference for the diagnosis and management of patients with PCOS.Methods All participants were recruited from the Reproductive Medical Center at Peking University Third Hospital between September 2015 and December 2016. PCOS group included 24 women with PCOS diagnosed according to the 2003 Rotterdam Criteria. Control group included 24 healthy women with a normal physical examination in the hospital physical examination center during the same period. The levels of serum IL-22, free fatty acid and the hormones and glycolipid markers and their correlations were compared between the two groups.Results Serum IL-22 in PCOS group was significantly lower than that in control group (P<0.05). Free Fatty acids in the PCOS group were significantly higher than the control group. The main manifestations were myristic acid (FFA 14:0), octadecanoic acid (FFA 18:0), octadecane acid (FFA 18:1), linoleic acid (FFA 18:2) and docosahexaenoic acid/DHA (FFA 22:6), with the corresponding P values as 0.003, 0.031, 0.009, 0.026, 0.010. IL-22 is negatively correlated with FPG, fasting insulin, HOMA-IR and TG (P<0.05).Conclusions erum IL-22 in patients with PCOS was significantly decreased, while free fatty acids were significantly increased. The glycolipid markers levels had a correlation with serum immune factor IL-22 in patients with PCOS, indicating the patients had a degree of abnormality in intestinal immunity which induced a decrease of IL-22. IL-22 may be a biomarker for diagnosing and predicting the severity of metabolic abnormalities in patients with PCOS.

Key words： polycystic ovary syndrome IL-22 free fatty acids metabolic disorders

收稿日期: 2021-03-24

基金资助:国家重点研发计划(2018YFC1003900,2018YFC1003200);国家自然科学基金(82022028,81730038,82001506);中国医学科学院医学与健康科技创新工程项目(2019-I2M-5-001);北京大学第三医院临床重点项目(BYSYZD2019020);中国博士后科学基金(2019M660367)

通讯作者: 庞艳莉(yanlipang@bjmu.edu.cn);乔杰(jie.qiao@263.net)

引用本文:

齐新宇, 庞艳莉, 乔杰. 多囊卵巢综合征患者血清IL-22和游离脂肪酸与糖脂标记物相关性的研究[J]. 中国生育健康杂志, 2021, 32(5): 431-436. QI Xinyu, PANG Yanli, QIAO Jie. Study on the correlation between serum IL-22, free fatty acids and glycolipid metabolites levels in patients with polycystic ovary syndrome. Chinese Journal of Reproductive Health, 2021, 32(5): 431-436.

链接本文:

http://cjrh.bjmu.edu.cn/CN/ 或 http://cjrh.bjmu.edu.cn/CN/Y2021/V32/I5/431

1 Li R,Zhang Q,Yang D,et al.Prevalence of polycystic ovary syndrome in women in China:a large community-based study.Hum Reprod,2013,28:2562-2569.
2 Norman RJ,Dewailly D,Legro RS,et al.Polycystic ovary syndrome.Lancet,2007,370:685-697.
3 Caserta D,Adducchio G,Picchia S,et al.Metabolic syndrome and polycystic ovary syndrome:an intriguing overlapping.Gynecol Endocrinol,2014,30:397-402.
4 Sabihi M,Bottcher M,Pelczar P,et al.Microbiota-dependent effects of IL-22. Cells,2020,9:2205.
5 Wang X,Ota N,Manzanillo P,et al.Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes.Nature,2014,514:237-241.
6 Dalmas E,Donath MY.A role for interleukin-22 in the alleviation of metabolic syndrome.Nat Med,2014,20:1379-1381.
7 Qi X,Yun C,Sun L,et al.Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome.Nat Med,2019,25:1225-1233.
8 Qi X,Yun C,Liao B,et al.The therapeutic effect of interleukin-22 in high androgen-induced polycystic ovary syndrome.J Endocrinol,2020,245:281-289.
9 Rotterdam ESHRE/ASRM- Sponsored PCOS Consensus Workshop Group.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.Fertil Steril,2004,81:19-25.
10 Brower MA,Hai Y,Jones MR,et al.Bidirectional Mendelian randomization to explore the causal relationships between body mass index and polycystic ovary syndrome.Hum Reprod,2019,34:127-136.
11 Escobar-Morreale HF.Polycystic ovary syndrome:definition,aetiology,diagnosis and treatment.Nat Rev Endocrinol,2018,14:270-284.
12 Caserta D,Adducchio G,Picchia S,et al.Metabolic syndrome and polycystic ovary syndrome:an intriguing overlapping.Gynecol Endocrinol,2014,30:397-402.
13 Iacobini C,Pugliese G,Blasetti FC,et al.Metabolically healthy versus metabolically unhealthy obesity.Metabolism,2019,92:51-60.
14 Niu Z,Lin N,Gu R,et al.Associations between insulin resistance,free fatty acids,and oocyte quality in polycystic ovary syndrome during in vitro fertilization.J Clin Endocrinol Metab,2014,99:E2269-E2276.
15 Rajska A,Buszewska-Forajta M,Rachon D,et al.Metabolomic insight into polycystic ovary syndrome-an overview.Int J Mol Sci,2020,21:4853.
16 Zhao Y,Fu L,Li R,et al.Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome:plasma metabolomics analysis.BMC Med,2012,10:153.
17 Li S,Chu Q,Ma J,et al.Discovery of novel lipid profiles in PCOS:do insulin and androgen oppositely regulate bioactive lipid production?.J Clin Endocrinol Metab,2017,102:810-821.
18 Pedersen H K,Gudmundsdottir V,Nielsen H B,et al.Human gut microbes impact host serum metabolome and insulin sensitivity.Nature,2016,535:376-381.
19 Cai W,Xu J,Li G,et al.Ethanol extract of propolis prevents high-fat diet-induced insulin resistance and obesity in association with modulation of gut microbiota in mice.Food Res Int,2020,130:108939.
20 Winer D A,Luck H,Tsai S,et al.The intestinal immune system in obesity and insulin resistance.Cell Metab,2016,23:413-426.
21 Dudakov J A,Hanash A M,van den Brink M R.Interleukin-22:immunobiology and pathology.Annu Rev Immunol,2015,33:747-785.
22 Dalmas E,Donath M Y.A role for interleukin-22 in the alleviation of metabolic syndrome.Nat Med,2014,20:1379-1381.